Last updated: September 14, 2026
Epcoritamab-bysp, marketed as Epkinly in the United States and Tepkinly in some international markets, is a subcutaneous CD20-directed CD3 T-cell engager developed by Genmab and AbbVie. The FDA granted accelerated approval in May 2023 for adults with relapsed or refractory diffuse large B-cell lymphoma after at least two lines of systemic therapy.[1] AbbVie reported initial U.S. sales of approximately $18 million in 2023, with revenue growth dependent on label expansion, treatment-center adoption, and conversion from intravenous bispecific antibodies and CAR-T therapy.[2]
The commercial opportunity is substantial but competitive. Epcoritamab has a differentiated subcutaneous administration model and activity across aggressive B-cell lymphomas. Its main risks are the limited initial indication, cytokine release syndrome management, competition from glofitamab and CAR-T products, payer restrictions, and the long-term manufacturing and intellectual-property durability of a bispecific antibody franchise.
What is epcoritamab-bysp and how does Epkinly work?
Epcoritamab-bysp is a bispecific antibody that binds CD20 on malignant B cells and CD3 on T cells. The interaction activates T cells and promotes targeted killing of CD20-positive B cells. Epkinly is administered subcutaneously using a step-up dosing schedule intended to reduce the severity of cytokine release syndrome, or CRS.[1]
What FDA indication does epcoritamab-bysp have?
The FDA approved Epkinly on May 19, 2023, under the accelerated approval pathway for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The indication includes:
- Diffuse large B-cell lymphoma, not otherwise specified
- DLBCL arising from indolent lymphoma
- High-grade B-cell lymphoma
- Patients who are not otherwise specified as candidates for more intensive treatment in the approved setting
The approval was based primarily on response data from the EPCORE NHL-1 study. The FDA label reported an overall response rate of approximately 61%, including complete responses in approximately 38% of treated patients.[1]
Accelerated approval creates a regulatory obligation to confirm clinical benefit in a postmarketing trial. Failure to verify benefit can expose the product to withdrawal proceedings under the FDA accelerated approval framework.
What formulation and delivery system does Epkinly use?
Epkinly is a ready-to-use subcutaneous injection supplied in single-dose vials. The product uses step-up dosing before the recommended full dose. The schedule reduces, but does not eliminate, CRS and immune effector cell-associated neurotoxicity syndrome, or ICANS.
Subcutaneous delivery is a commercial differentiator against intravenous bispecific antibodies. It can reduce infusion-chair time and may support outpatient administration after the initial step-up doses. The operational advantage depends on institutional protocols, nursing capacity, observation requirements, and payer reimbursement.
What is the commercial market for epcoritamab-bysp?
The addressable market includes patients with relapsed or refractory aggressive B-cell lymphoma who have exhausted at least two prior therapies. This population is clinically high risk and has limited treatment options, but it is smaller than the first-line lymphoma market.
Epcoritamab competes across several treatment sequences:
| Treatment setting |
Principal alternatives |
Commercial implication |
| Third-line and later DLBCL |
CAR-T, polatuzumab vedotin, tafasitamab, loncastuximab, clinical trials |
Epcoritamab can be used after multiple prior therapies and may be available to patients who are not CAR-T candidates |
| Post-CAR-T relapse |
Glofitamab, epcoritamab, salvage therapy, trials |
A growing but clinically difficult segment |
| Patients unsuitable for CAR-T |
Bispecific antibodies, antibody-drug conjugates, chemotherapy |
Subcutaneous administration and off-the-shelf availability support adoption |
| Earlier-line disease |
Emerging bispecific and combination studies, CAR-T, chemotherapy |
Label expansion could materially increase volume |
The key commercial issue is whether epcoritamab remains a later-line product or moves into earlier treatment settings. Earlier-line use would increase the eligible population and treatment duration, but it would also place Epkinly into direct competition with CAR-T, frontline immunochemotherapy, and other bispecific antibodies.
What is the financial trajectory of Epkinly?
AbbVie reported approximately $18 million in Epkinly net revenues for 2023, its first partial commercial year.[2] The initial figure reflects a short launch period after the May 2023 approval rather than mature demand.
| Period |
Reported or estimated commercial position |
Main driver |
| 2023 |
Approximately $18 million in AbbVie-reported net sales |
Initial U.S. launch and limited treatment-center activation |
| 2024 |
Growth phase |
Wider physician adoption, international launches, and use in post-CAR-T and CAR-T-ineligible patients |
| 2025 onward |
Dependent on label expansion and treatment duration |
Earlier-line studies, combination studies, and competitive positioning |
Genmab and AbbVie share the economics under their collaboration agreement. Genmab receives commercial economics from the program, while AbbVie leads commercialization in major markets under the companies' strategic partnership.[3]
What drives Epkinly revenue growth?
Revenue growth depends on five variables:
- The number of eligible relapsed or refractory DLBCL patients.
- The percentage of physicians choosing a bispecific antibody instead of CAR-T or another salvage therapy.
- Treatment duration and the proportion of patients reaching sustained response.
- Expansion into earlier treatment lines.
- Geographic reimbursement and treatment-center access.
Epcoritamab's subcutaneous administration can increase treatment capacity relative to intravenous products. Its off-the-shelf availability can also be commercially important because CAR-T treatment requires leukapheresis, manufacturing, lymphodepletion, and a specialized treatment network.
How does treatment duration affect revenue?
Epkinly uses a fixed step-up and maintenance schedule, with dosing intervals that become less frequent over time. Patients who achieve durable responses can generate revenue over many months. The commercial model is therefore different from a one-time cellular therapy.
Treatment persistence is constrained by disease progression, adverse events, discontinuation, and competing treatment options. The net revenue opportunity is higher if epcoritamab is used as a durable treatment rather than as a short bridge to another therapy.
How does epcoritamab compare with competing lymphoma drugs?
The most direct bispecific competitor is Columvi, or glofitamab, developed by Roche. Lunsumio, or mosunetuzumab, developed by Roche, is another CD20xCD3 bispecific antibody used in B-cell lymphoma. CAR-T products such as Yescarta, Kymriah, and Breyanzi compete for overlapping patients but have different logistics and treatment economics.
| Product |
Developer |
Target |
Administration |
Key competitive distinction |
| Epkinly, epcoritamab-bysp |
AbbVie/Genmab |
CD20xCD3 |
Subcutaneous |
Off-the-shelf treatment with outpatient potential |
| Columvi, glofitamab-gxbm |
Roche |
CD20xCD3 |
Intravenous |
Fixed-duration therapy and step-up dosing |
| Lunsumio, mosunetuzumab-axgb |
Roche |
CD20xCD3 |
Intravenous |
Established bispecific option in follicular lymphoma |
| Yescarta, axicabtagene ciloleucel |
Kite/Gilead |
CD19 CAR-T |
One-time cellular therapy |
High response potential with complex manufacturing |
| Breyanzi, lisocabtagene maraleucel |
Bristol Myers Squibb |
CD19 CAR-T |
One-time cellular therapy |
Expanded lymphoma positioning and treatment-center network |
| Kymriah, tisagenlecleucel |
Novartis |
CD19 CAR-T |
One-time cellular therapy |
Earlier CAR-T market presence |
How does Epkinly compare with Columvi?
Epcoritamab and glofitamab have similar biological concepts but different product characteristics. Epkinly is administered subcutaneously, while Columvi is administered intravenously. Glofitamab uses a defined treatment duration in its approved regimen, while epcoritamab is administered on a continuing schedule until disease progression or unacceptable toxicity under the initial label.
The comparison is likely to center on:
- Complete response rates and durability
- CRS frequency and severity
- Hospitalization requirements
- Treatment duration
- Site-of-care economics
- Time to treatment
- Payer and physician familiarity
- Results in post-CAR-T patients
Cross-trial comparisons are unreliable because patient populations, prior treatments, follow-up periods, and response assessments differ.
What is the regulatory status and exclusivity timeline for epcoritamab-bysp?
The FDA granted Epkinly accelerated approval in May 2023.[1] As a biologic, Epkinly is regulated under the Public Health Service Act. It does not receive the small-molecule Hatch-Waxman exclusivity framework used for drugs listed in the Orange Book.
| Regulatory item |
Status |
| FDA approval pathway |
Accelerated approval |
| Initial approval date |
May 19, 2023 |
| Initial indication |
Relapsed or refractory large B-cell lymphoma after at least two prior lines |
| Biologic reference product |
Epkinly, epcoritamab-bysp |
| Statutory biologic exclusivity |
Generally 12 years from first licensure |
| Earliest potential U.S. biosimilar application date |
Four years after first licensure |
| Earliest potential biosimilar approval date |
Generally 12 years after first licensure, subject to litigation and regulatory factors |
| Potential exclusivity endpoint |
Approximately May 2035, before any pediatric extension |
The 12-year reference-product exclusivity period points to approximately May 2035, assuming the first licensure date remains May 2023 and no pediatric extension applies. Patent rights may extend beyond or expire before that date, depending on the claims, patent term adjustment, patent-term extension, and jurisdiction.
What patents protect epcoritamab-bysp and is Epkinly listed in the Orange Book?
Epkinly is a biologic and does not have an Orange Book listing equivalent to a conventional small-molecule drug. Biologic patent information is addressed through the Purple Book and the patent-exchange procedures under the Biologics Price Competition and Innovation Act.
The principal IP categories are expected to include:
- The epcoritamab antibody sequence
- CD20xCD3 bispecific antibody architecture
- Antibody production and cell-line technology
- Formulation and stability
- Subcutaneous dosing regimens
- Step-up dosing methods
- Treatment of specific B-cell malignancies
- Combination use with other antineoplastic agents
A full freedom-to-operate assessment requires review of issued U.S. patents, pending applications, international counterparts, terminal disclaimers, patent-term adjustment, and claim scope. Public regulatory exclusivity alone does not establish the full patent expiry profile.
What formulation patents protect Epkinly?
Potential formulation protection can cover concentration, buffer system, excipients, stability, vial configuration, and storage conditions. Formulation claims matter commercially because they may restrict follow-on products even when the core antibody sequence is no longer enforceable.
For a subcutaneous biologic, formulation and delivery claims can have particular value because the product must maintain stability, viscosity, concentration, and tolerability at a volume suitable for injection.
What method-of-use patents protect epcoritamab?
Method-of-use claims may cover:
- Treatment of DLBCL after specified prior therapies
- Treatment after CAR-T failure
- Treatment of follicular lymphoma or other CD20-positive malignancies
- Specific step-up dosing schedules
- Combination with immunomodulators or chemotherapy
- Management of CRS through staged dosing
Method-of-use patents can create litigation risk for biosimilars and branded competitors, but their practical value depends on claim breadth, enforceability, physician prescribing behavior, and the ability to design around the claims.
When could epcoritamab-bysp lose exclusivity?
The first major U.S. biosimilar risk is unlikely before the statutory biologic exclusivity period reaches approximately May 2035. A biosimilar sponsor could prepare and file an application earlier under the BPCIA framework, but commercial launch would depend on regulatory approval, patent litigation, settlement terms, and any applicable exclusivity rights.
The actual launch date could be affected by:
- Issued composition-of-matter patents
- Formulation and dosing patents
- Patent-term adjustment
- Patent-term extension
- Patent litigation
- BPCIA patent-exchange proceedings
- Settlement agreements
- Pediatric exclusivity
- Biosimilar interchangeability and substitution rules
Unlike small-molecule generics, biosimilar entry typically requires a more extensive comparability program and does not automatically result in pharmacy-level substitution in every setting.
Are there Paragraph IV challenges or patent settlements for Epkinly?
Paragraph IV certifications apply to patents listed for small-molecule products in the Orange Book. Because Epkinly is a biologic, the relevant framework is the BPCIA rather than a traditional Paragraph IV challenge.
There was no publicly established commercial biosimilar challenge or settlement affecting Epkinly in the early post-launch period covered by the FDA approval and company disclosures cited here. The absence of an announced challenge does not eliminate future litigation risk. Biosimilar sponsors may pursue patent disputes through BPCIA procedures, declaratory actions, or other patent litigation routes.
How strong is the epcoritamab patent estate?
Epcoritamab has a potentially strong exclusivity position through the combination of biologic exclusivity, antibody sequence rights, platform technology, formulation protection, and dosing patents. The strength of the estate depends on whether core composition claims remain valid and enforceable.
| Patent-strength factor |
Assessment |
| Regulatory exclusivity |
Strong through approximately 2035 |
| Core antibody protection |
Potentially strong if broad composition claims remain valid |
| Formulation protection |
Important for defending the commercial presentation |
| Dosing and method claims |
Valuable but more vulnerable to design-around and use-pattern issues |
| Biosimilar complexity |
Moderate to high because of analytical and clinical comparability requirements |
| Competitive substitution |
High because other CD20xCD3 products and CAR-T therapies address overlapping patients |
| Litigation visibility |
Limited publicly disclosed litigation in the early launch period |
The main weakness is that regulatory exclusivity does not prevent competition from non-biosimilar products. Columvi, Lunsumio, CAR-T therapies, antibody-drug conjugates, and future bispecifics can compete without infringing epcoritamab patents.
What licensing deal supports epcoritamab-bysp?
Genmab and AbbVie entered a broad collaboration covering epcoritamab and other oncology programs. AbbVie obtained rights to develop and commercialize epcoritamab in specified territories, while Genmab retained economic participation through the collaboration structure.[3]
The deal gives Epkinly access to:
- AbbVie's global commercial infrastructure
- Genmab's antibody and bispecific expertise
- Shared development resources
- Expanded clinical development capacity
- Joint positioning across B-cell malignancies
The collaboration reduces commercialization risk compared with a single-company launch. It also creates dependence on alignment between the two companies over development priorities, geographic strategy, and lifecycle investment.
What generic and biosimilar launch risks exist for Epkinly?
Near-term risk comes primarily from therapeutic competition, not conventional generic entry. A biosimilar cannot legally enter merely because the reference product faces slower growth. It must satisfy FDA requirements for biosimilarity and navigate patent barriers.
Commercial launch risk is more immediate in the following areas:
- Glofitamab gaining preference through a fixed-duration regimen
- CAR-T moving into earlier lines
- New bispecifics with improved safety or dosing
- Payers preferring lower-cost alternatives
- Reduced treatment duration because of disease progression
- Hospital restrictions on outpatient administration
- CRS-related treatment costs
- Failure of confirmatory studies supporting accelerated approval
What is the geographic coverage of epcoritamab-bysp?
AbbVie and Genmab have pursued approval and commercialization across major oncology markets. The United States remains strategically important because of the size of the relapsed DLBCL market, reimbursement infrastructure, and early uptake of bispecific antibodies.
International revenue will depend on:
- European Commission and national reimbursement decisions
- Health technology assessments
- Country-specific pricing negotiations
- Availability of CAR-T treatment centers
- Hospital procurement rules
- Local biologic competition
- Manufacturing and distribution capacity
International markets may produce slower uptake because treatment pathways and reimbursement for outpatient bispecific antibodies differ substantially from the United States.
What manufacturing and IP barriers affect epcoritamab-bysp?
Epcoritamab manufacturing requires mammalian cell culture, antibody purification, quality control, aseptic filling, and validated supply-chain processes. The bispecific format creates analytical and manufacturing requirements beyond those for some conventional monoclonal antibodies.
Key barriers include:
- Control of product-related variants
- Consistency of bispecific pairing
- Potency assays for dual-target activity
- Aggregation and stability control
- Sterile fill-finish capacity
- Cold-chain distribution
- Comparability after manufacturing changes
- Scale-up for earlier-line indications
These manufacturing requirements can delay biosimilar entry and increase the cost of commercial expansion. They also make supply reliability a factor in treatment-center adoption.
What patent litigation affects epcoritamab-bysp?
No major publicly disclosed patent litigation was established in the cited early commercial period. The principal future litigation risk is expected to arise from biosimilar entry and possible disputes over antibody composition, formulation, dosing, and manufacturing claims.
The more immediate legal exposure is regulatory. If confirmatory trials fail to verify clinical benefit, the FDA could require label changes or pursue withdrawal of the accelerated approval under applicable procedures.[1]
Key Takeaways
- Epcoritamab-bysp, marketed as Epkinly, is a subcutaneous CD20xCD3 bispecific antibody from Genmab and AbbVie.
- The FDA granted accelerated approval on May 19, 2023, for relapsed or refractory large B-cell lymphoma after at least two prior lines of therapy.
- AbbVie reported approximately $18 million in Epkinly sales during the partial 2023 launch year.
- Revenue growth depends on treatment-center adoption, persistence, international reimbursement, and earlier-line label expansion.
- The main competitors are glofitamab, mosunetuzumab, CAR-T therapies, and other emerging bispecific antibodies.
- Epkinly is a biologic, so the BPCIA and Purple Book framework applies rather than traditional Orange Book Paragraph IV procedures.
- Statutory biologic exclusivity points to approximately May 2035, subject to the precise first-licensure date and any pediatric extension.
- The patent estate may include antibody sequence, bispecific architecture, formulation, dosing, method-of-use, and manufacturing claims.
- Near-term commercial risk comes from clinical competition and treatment economics rather than conventional generic substitution.
- The principal regulatory risk is failure of confirmatory studies required under accelerated approval.
FAQs
Is epcoritamab-bysp a CAR-T therapy?
No. Epcoritamab-bysp is an off-the-shelf bispecific antibody. It activates a patient's existing T cells by binding CD3 and CD20. CAR-T therapy requires collection and genetic modification of the patient's T cells.
Is Epkinly administered intravenously?
No. Epkinly is administered subcutaneously after step-up dosing. This distinguishes it from intravenous bispecific antibodies such as glofitamab and mosunetuzumab.
Does Epkinly have a biosimilar?
No publicly established biosimilar had reached commercial launch in the early post-approval period. The first potential biosimilar approval date is generally constrained by the 12-year U.S. biologic exclusivity period.
What is the largest financial risk for Epkinly?
The largest commercial risk is failure to secure earlier-line use before competing bispecific antibodies and CAR-T products establish treatment preference. A narrow later-line label limits the number of eligible patients and total revenue.
Can Epkinly be used after CAR-T failure?
Epcoritamab has been studied in patients with prior CAR-T exposure, and post-CAR-T relapse is an important commercial segment. Actual use depends on the approved label, clinical evidence, physician judgment, and payer policy.
References
-
U.S. Food and Drug Administration. (2023). Epkinly (epcoritamab-bysp) prescribing information. FDA.
-
AbbVie Inc. (2023). 2023 annual report. AbbVie.
-
Genmab A/S. (2023). Annual report 2023. Genmab.
-
Thieblemont, C., Phillips, T., Ghesquieres, H., et al. (2023). Epcoritamab, a T-cell-engaging bispecific antibody, in relapsed or refractory large B-cell lymphoma. The Lancet, 402(10396), 41-51.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
U.S. Food and Drug Administration. (2023). New drug therapy approvals 2023. FDA.
